[Salpêtrière erythrophobia questionnaire validation]. / Validation du questionnaire d'éreutophobie de la Salpêtrière.

OBJECTIVE: To study the main psychometric characteristics of the Salpêtrière Erythrophobia Questionnaire (SEQ) in a clinical and non-clinical sample. METHOD: Patients with social phobia (SP) (n = 212), patients with other anxiety disorders (n = 146), and participants from the general population (n = 171) were distributed in the 3 study groups. They completed the SEQ as well as several anxiety and depression scales. Erythrophobia was diagnosed according to standardized criteria and assessed using the Clinical Global Impression Scale. RESULTS: The SEQ scale factor pattern is clear, with only 1 factor explaining 83.9% of total score and a Cronbach's alpha consistency coefficient of 0.96. The SEQ score is significantly correlated to a dimensional hetero-evaluation of the fear of blushing (rho = 0.91) and SP measures (rho = 0.23 to 0.55). The SEQ mean score is higher in the SP group and even higher in the erythrophobia group. A score of 7 out of 24 makes it possible to identify erythrophobia with 92.1% sensitivity and 87.7% specificity. The SEQ test-retest reliability at 15-day interval is satisfactory (ICC = 0.83). CONCLUSION: The SEQ is a valid and sensitive tool to screen and measure erythrophobia. It can be used in psychopathological and therapeutic studies of this pathology.

Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report.

Anti-NMDA-Receptor encephalitis is a severe form of encephalitis that was recently identified in the context of acute neuropsychiatric presentation. Here, we describe the case of a 17-year-old girl referred for an acute mania with psychotic features and a clinical picture deteriorated to a catatonic state. Positive diagnosis of anti-NMDA-receptor encephalitis suggested specific treatment. She improved after plasma exchange and immunosuppressive therapy. Post-cognitive sequelae (memory impairment) disappeared within 2-year follow-up and intensive cognitive rehabilitation.